Analysts Estimate Janux Therapeutics, Inc. (JANX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 05/02/23
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid TumorsBusiness Wire • 04/20/23
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsBusiness Wire • 03/10/23
Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care ConferenceBusiness Wire • 02/14/23
Janux Therapeutics, Inc. (JANX) Surges 5.9%: Is This an Indication of Further Gains?Zacks Investment Research • 02/14/23
Janux Therapeutics, Inc. (JANX) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/10/23
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid TumorsBusiness Wire • 12/27/22
Here's Why Janux Therapeutics, Inc. (JANX) Looks Ripe for Bottom FishingZacks Investment Research • 11/23/22
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsBusiness Wire • 11/10/22
Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate CancerBusiness Wire • 10/12/22
Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in SeptemberBusiness Wire • 08/31/22
Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsBusiness Wire • 08/09/22
Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate CancerBusiness Wire • 05/31/22
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business HighlightsBusiness Wire • 05/10/22
Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTrBusiness Wire • 04/26/22
Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial ResultsBusiness Wire • 03/18/22